SCHEMBL7685136

SCHEMBL7685136

CCc1c(C(=O)O)c(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.53
ABCB11 O95342 1/20 0.53
ABCB1 P08183 3/20 0.43
HTT P42858 2/20 0.42
TSHR P16473 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GRIA2 P42262 1/20 0.41
GRIA4 P48058 1/20 0.41
SRD5A2 P31213 1/20 0.41
MAPT P10636 2/20 0.40
HPGD P15428 1/20 0.40
OXER1 Q8TDS5 1/20 0.40
NR4A1 P22736 1/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.38
PTGS1 P23219 3/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7683947 0.88 PTGS2 (0.50) PTGS2ABCB11ABCB1HTTTSHR
SCHEMBL7684797 0.87 PTGS2 (0.46) PTGS2ABCB11HTTTSHRALDH1A1
SCHEMBL8607662 0.86 PTGS2 (0.57) PTGS2ABCB11ABCB1HTTTSHR
SCHEMBL7675435 0.86 PTGS2 (0.57) PTGS2ABCB11ABCB1HTTTSHR
SCHEMBL11713537 0.85 PTGS2 (0.53) PTGS2ABCB11ABCB1HTTTSHR
SCHEMBL10880899 0.82 PTGS2 (0.51) PTGS2ABCB11ABCB1HTTTSHR
SCHEMBL11182285 0.81 PTGS2 (0.50) PTGS2ABCB11ABCB1HTTTSHR
SCHEMBL10879088 0.81 PTGS2 (0.50) PTGS2ABCB11ABCB1HTTTSHR
SCHEMBL7677988 0.79 PTGS2 (0.42) PTGS2ABCB11HTTTSHRALDH1A1
SCHEMBL8607608 0.77 ABCB11 (0.42) PTGS2ABCB11HTTTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed
US-5721347-A Esters and amides of substituted pyrrole acetic acids CELL PATHWAYS, INC. (US) 1998-02-24 US disclosed
EP-0485157-A2 Esters and amides of substituted pyrrole acetic acids FGN, INC. (US) 1992-05-13 EP disclosed
US-4070368-A ACYLATION, DECARBOXYLATION MCNEIL LABORATORIES, INCORPORATED (US) 1978-01-24 US disclosed
US-3952012-A MULTISTAGE MCNEIL LABORATORIES, INCORPORATED (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A PTGS2 887/4885ABCB11 2317/4885ABCB1 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.